A couple weeks after activist attack, GlaxoSmithKline unveils big plans to create a UK biotech hub

A couple weeks after activist investor Elliott began its long-awaited attack on CEO Emma Walmsley, GlaxoSmithKline has unveiled a plan to sell over a third of the land at its Stevenage, UK, site to create “one of Europe’s largest ‘clusters’ for biotechnology” and early-stage life sciences companies.